The FDA granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO, a dual-targeted therapy for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based chemotherapy and anti-PD-(L)1 antibody treatment. This marks the first dual-targeted treatment in this cancer setting, targeting EGFR and MET simultaneously. Halozyme's ENHANZE technology enables subcutaneous delivery, improving patient convenience and expanding treatment options. This approval extends the drug's use beyond lung cancer, addressing a high unmet need in advanced head and neck cancer patients.
Following the FDA's accelerated approval of Johnson & Johnson's RYBREVANT FASPRO for advanced head and neck cancer, shares of Johnson & Johnson are trading slightly down by 0.35% at USD 271.36 as of Nov 06, 2026 22:01 WIB on Pluang. Meanwhile, Halozyme Therapeutics, whose ENHANZE technology is part of the treatment, saw a sharper decline of 9.78% to USD 110.93. Johnson & Johnson's market cap stands at $655.56 billion, reflecting its large scale in the health sector.
